Figure 1.
Association of alpha-1 antitrypsin (AAT) concentrations between healthy controls individuals and sickle cell disease (SCD) patients in steady state, and with mutations in SERPINA1 gene between steady-state SCD patients and individuals of control group. (A) AAT levels between SCD patients and control group; (B) AAT levels between SCD patients and control group with proteinase inhibitor (PI)*MM genotype; (C,D) association of SERPINA1 gene mutations and AAT concentration among SCD patients. SCD patients with genotype PI*MM had higher AAT levels than patients with mutant genotype analyzed separately (PI*MS and PI*SS) and together. (E,F) Association of SERPINA1 gene mutations and AAT concentration among control group individuals. Control groups individuals with genotype PI*MM had higher AAT levels than individuals with mutant genotype analyzed separately (PI*MS and PI*MZ) and together.